Loading...

AUTL AUTOLUS THERAPEUTICS PLC US FDA Inspections 8-K Filing

TLS

TL

AUTOLUS THERAPEUTICS PLC

(AUTL)

2024 8-K

Show Summary

Summary

Annual Report and AGM Notice

Financial Statements

Investor Update

Management Changes

Financial Results

Corporate Update

Financial Results

Corporate Update

Management Change

Lease Amendment

Financial Results and Corpo...

Financial Statements and Ex...

Clinical Study Data Announc...

Financial Results and Corpo...

Rescheduled Conference Call...

Management Changes

Accounting Error

Conference Call Transcript

Financial Results and Manag...

Corporate Presentation

Underwriting Agreement

License and Option Agreemen...

FDA Accepts BLA for obecabt...

Appointment of New Director

Management Changes

ASH Annual Meeting Presenta...

Regulation FD Disclosure

External Links:

Autolus Therapeutics plc announced that the FDA has accepted its Biologics License Application for obecabtagene autoleucel for patients with relapsed/refractory Adult B-Cell Acute Lymphoblastic Leukemia, with a target action date of November 16, 2024.

AI Assistant

AUTOLUS THERAPEUTICS PLC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.